NDC product
acetylcysteine
NDC 0574-0805 · Padagis US LLC
Key facts
| Product NDC | 0574-0805 |
|---|---|
| Proprietary name | acetylcysteine |
| Nonproprietary name | Acetylcysteine |
| Substances | ACETYLCYSTEINE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | Padagis US LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA021539 |
| Pharmacologic classes | Antidote [EPC], Antidote for Acetaminophen Overdose [EPC], Decreased Respiratory Secretion Viscosity [PE], Increased Glutathione Concentration [PE], Mucolytic [EPC], Reduction Activity [MoA] |
| Marketing start | Dec 20, 2012 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: